An RPE tear is a sudden rip in the thin brown “support layer” under the retina called the retinal pigment epithelium (RPE). This layer normally sits flat on a thin sheet called Bruch’s membrane and helps nourish the light-sensing cells. In many eyes there is a small “blister” or pigment-epithelial detachment (PED) where the RPE has lifted up. When the tension gets too high—because of pressure from fluid or blood under the RPE, or because of pulling from a scarred blood-vessel membrane—the RPE can split. One edge usually curls or “scrolls” back on itself, and the other side becomes a bare patch where the RPE is missing and the underlying layer is exposed. This event can cause a sudden drop in central vision, especially if the tear involves the fovea (the very center of seeing). PubMed Central

A retinal pigment epithelial (RPE) tear is a rip in the thin, dark cell layer that sits under the retina and feeds it. This layer is called the retinal pigment epithelium. When it tears, the RPE peels back like a flap, and the pale base layer beneath it (Bruch’s membrane/choroid) becomes exposed. This can suddenly blur or distort central vision if the tear crosses the macula (the seeing center). RPE tears most often happen in eyes with age-related macular degeneration (AMD) that have a bulge under the RPE called a pigment epithelial detachment (PED). Tears can occur spontaneously as part of the disease or after treatment for the abnormal vessels in wet AMD (especially around large/steep PEDs). EyeWiki+2EyeWiki+2

Mechanically, two forces are key: 1) pressure from fluid trapped under the RPE inside a PED and 2) traction from a contracting choroidal neovascular membrane (a scar-like sheet of abnormal vessels) tugging on the RPE from below. Both can stress the RPE until it rips. PubMed

---

Types

Clinicians describe RPE tears in several practical ways. Using more than one label for the same case is normal.

1) By size and foveal involvement (Sarraf grading):

• Grade 1: tiny tear (<200 μm).

• Grade 2: small tear (200 μm to 1 disc diameter).

• Grade 3: large tear (>1 disc diameter).

• Grade 4: any tear that involves the fovea (these carry the worst visual prognosis). Lippincott Journals

2) By cause or setting:

• Spontaneous (part of the natural history of a high-risk PED).

• Treatment-associated (after anti-VEGF injection, photodynamic therapy, or thermal laser). PubMed Central+1

3) By shape and appearance:

• Crescent-shaped tears with a clear, scrolled edge.

• Concentric “island” tears where a round island of scrolled RPE sits inside a larger area of RPE loss. (These patterns are what clinicians actually see at the slit lamp and on imaging.) PubMed Central

4) By contents:

• Hemorrhagic (with subretinal blood) or non-hemorrhagic; hemorrhage often worsens outcomes. PubMed Central

---

Causes

RPE tears have many triggers, but they usually share the same final pathway: a lifted RPE (PED) plus pressure and/or pull. Here are common and well-documented causes or contexts:

1. Neovascular (“wet”) age-related macular degeneration (AMD) with a vascularized PED—the most common setting worldwide. The abnormal vessel complex pulls on the RPE until it rips. PubMed

2. Anti-VEGF injection in a high-risk PED—treatment can rapidly shrink the vessel membrane, increasing traction and precipitating a tear in some eyes at risk. (Risk is highest with bigger/steeper PEDs.) PubMed

3. Natural history of a vascularized PED without treatment—tears also occur spontaneously as the PED grows and pressure rises. PubMed

4. Photodynamic therapy (PDT)—PDT can sometimes trigger a tear, especially in eyes with large PEDs or certain choroidal disorders. PubMedNature

5. Thermal laser to macular neovascularization—older treatments with thermal laser were known to cause RPE rips in some cases. PubMed Central

6. Polypoidal choroidal vasculopathy (PCV)—a cousin of AMD with branching vessels and polyps under the retina; microrips and full tears have been reported. PubMed Central

7. Central serous chorioretinopathy (CSC), including bullous CSC—a thick, fibrin-rich detachment can stretch the RPE and lead to a tear; PDT used for CSC can also precipitate tears. PubMed Central+1

8. High myopia with macular neovascularization—thinned tissues and type 1 CNV increase risk. PubMed Central

9. Angioid streaks—brittle Bruch’s membrane and secondary CNV can set the stage for RPE tears. PubMed Central

10. Choroidal tumors (melanoma or metastasis)—mass effect, fluid, or treatment can contribute. PubMed Central

11. Light chain deposition disease—rare systemic condition reported with PEDs and tears. PubMed Central

12. Traumatic chorioretinopathy—blunt trauma can trigger rips in predisposed tissue. PubMed Central

13. Vitreomacular adhesion/traction in the presence of a PED—added shear traction on the RPE. PubMed Central

14. Massive submacular hemorrhage—the clot can contract and distort the RPE/retina complex. PubMed Central

15. Hypotony with choroidal detachment (e.g., after trabeculectomy or drainage device)—pressure changes can lead to RPE tears in rare cases. PubMed Central+1Cureus

16. Combined or repeated therapies (e.g., PDT plus anti-VEGF) in a high-risk PED. PubMed Central

17. Steroid-associated CSC—exogenous steroids can worsen CSC and PEDs, indirectly raising tear risk. PubMed Central

18. Presumed ocular histoplasmosis syndrome (POHS) with CNV—reported in early series. PubMed

19. Pathologic myopia–related structural thinning (distinct from #8’s CNV emphasis). PubMed Central

20. Idiopathic—in some eyes, no single external trigger is found. PubMed

Rates vary with the population studied. In anti-VEGF–treated, high-risk vascularized PEDs, reported rates of tears range roughly 10–20% in some series; broader AMD cohorts show lower overall incidences. The specific number depends on PED size, height, and disease mix. PubMedPubMed CentralNature

---

Symptoms

1. Sudden blurry central vision—letters look washed out or missing because the center of sight is affected.

2. A dark or gray patch in the center (a “scotoma”) where the RPE has torn.

3. Wavy or bent lines—straight lines on a page or Amsler grid look distorted (metamorphopsia).

4. Patchy missing spots in reading lines as the eye moves across text.

5. Colors look dull or less vivid than before.

6. Poor contrast—gray on white or faint print is harder to see.

7. Glare sensitivity—bright light makes vision worse or hazier.

8. Trouble reading—especially fine print or when the tear reaches the fovea.

9. Difficulty recognizing faces from a normal distance.

10. Slow visual recovery after light exposure (sometimes noticed as “photostress”).

11. Night vision complaints if a large area of RPE is lost.

12. A smaller or larger appearance of objects (micropsia or macropsia) due to retinal shape changes.

13. Visual fluctuation with fluid shifts from underlying disease.

14. Flashes or shimmering if traction and fluid irritate the retina.

15. Eye seems fine physically—there is rarely pain or redness; the problem is purely visual.

(These are typical patient-reported problems in RPE tears and related macular conditions; the exact symptom set depends on tear size and foveal involvement.) PubMed Central

---

Diagnostic tests

A) Physical examination

1. Best-corrected visual acuity (BCVA)
   What it shows: how much central vision is lost.
   Why it helps: baseline and follow-up anchor; worse if the fovea is involved.

2. Pinhole test
   What it shows: whether blur is optical (improves with pinhole) or retinal (often does not improve).
   Why it helps: quick way to confirm macular, not refractive, origin of blur.

3. Pupil exam for RAPD
   What it shows: relative retinal/optic nerve dysfunction if very asymmetric damage exists.
   Why it helps: rules out optic-nerve causes; macular disease alone usually shows no RAPD unless severe.

4. Slit-lamp biomicroscopy with a macular lens (e.g., 78D/90D)
   What it shows: a rolled, hyperpigmented RPE edge next to a sharply demarcated pale “bare” area.
   Why it helps: classic appearance of a tear on clinical exam. PubMed Central

5. Dilated binocular indirect ophthalmoscopy
   What it shows: the tear’s extent, any peripheral fluid or hemorrhage.
   Why it helps: full-retina check for associated findings.

B) Manual / bedside functional tests

6. Amsler grid
   What it shows: central distortion or missing squares.
   Why it helps: quick, sensitive home/office monitor for metamorphopsia.

7. Photostress recovery test
   What it shows: delayed recovery when the macula/RPE are dysfunctional.
   Why it helps: distinguishes macular disease from optic-nerve disease in a simple way.

8. Contrast sensitivity (e.g., Pelli-Robson chart)
   What it shows: reduced ability to see faint contrasts.
   Why it helps: detects macular function loss not captured by Snellen acuity.

9. Color vision testing (Ishihara/HRR)
   What it shows: desaturation or acquired color defects when the fovea is involved.
   Why it helps: documents central cone pathway impact.

C) Laboratory / pathological

10. Syphilis serology (RPR/VDRL + treponemal confirmatory test)
    What it shows: rules out an inflammatory/infectious mimic of serous detachments.
    Why it helps: rare, but important in atypical cases. (Labs are adjunctive—RPE tear itself is an imaging diagnosis.) PubMed

11. Systemic steroid / endocrine work-up when CSC is suspected (history of steroid use, cortisol testing when indicated)
    What it shows: steroid-related CSC risk contributing to PED and tears.
    Why it helps: guides systemic management to reduce recurrence risk. PubMed Central

D) Electrodiagnostic

12. Electro-oculogram (EOG)
    What it shows: objective RPE function (Arden ratio; <1.7 is generally abnormal).
    Why it helps: documents global RPE health; useful in complex or bilateral disease. PubMed

13. Multifocal electroretinogram (mfERG)
    What it shows: localized macular signal reductions that map to the tear/atrophy area.
    Why it helps: correlates structure to function beyond acuity. PubMed Central

14. Visual evoked potential (VEP)
    What it shows: cortical response to visual stimuli; usually normal in isolated macular disease but can help exclude post-retinal causes.
    Why it helps: clarifies that the deficit is retinal/macular rather than optic-nerve/brain.

E) Imaging

15. Spectral-domain OCT (SD-OCT)
    What it shows: the break in the hyper-reflective RPE line, a wavy/rolled free edge, and increased light transmission (hyper-transmission) through the RPE-absent zone; also maps PED height and foveal involvement.
    Why it helps: the single best anatomic test to confirm a tear and follow healing/scar formation. PubMed Central

16. OCT Angiography (OCTA)
    What it shows: flow within the type-1 macular neovascular network under the RPE.
    Why it helps: defines the traction-producing membrane without dye.

17. Fluorescein angiography (FA)
    What it shows: a “window defect” (bright hyperfluorescence) in the bare area and blocked fluorescence at the rolled RPE; in some vascularized PEDs a peripheral “ring sign” may mark the cleavage plane in eyes at risk.
    Why it helps: classic dye pattern that supports the diagnosis and risk assessment. PubMed Central

18. Indocyanine green angiography (ICGA)
    What it shows: branching vascular networks/polyps in PCV, or type-1 membranes under the RPE.
    Why it helps: explains why traction exists and guides treatment choice. PubMed

19. Fundus autofluorescence (FAF)
    What it shows: dark (hypo-autofluorescent) signal where RPE is gone and bright (hyper-autofluorescent) signal along the scrolled RPE edge.
    Why it helps: fast, non-invasive map of RPE loss vs. survival. Europe PMC

20. Color fundus photography / widefield imaging
    What it shows: documentation of the crescent-shaped tear margin, hemorrhage, and PED profile over time.
    Why it helps: objective baseline and counseling tool.

Non-pharmacological treatments (therapies & others)

(Each item explains the description, purpose, and “how it helps.”)

1. Education & shared decision-making
   Description: Your retina specialist explains what an RPE tear is, what treatments can and cannot do, and what to watch for.
   Purpose: Reduces anxiety, aligns expectations, and supports adherence to follow-up and injections if needed.
   Mechanism: Understanding the disease improves timely care and safer choices.

2. Close observation with OCT imaging
   Description: Regular optical coherence tomography (OCT) scans track the tear edges, subretinal/intraretinal fluid, and the PED.
   Purpose: Detects activity early and guides treatment frequency.
   Mechanism: OCT shows microscopic fluid and tissue changes long before you feel them. EyeWiki

3. Home vision checks (Amsler grid/app)
   Description: A 10-second daily check for new wavy lines, gray patches, or blank spots.
   Purpose: Triggers quick contact with your clinic if changes appear.
   Mechanism: Early symptom capture → earlier clinic action.

4. Structured follow-up schedule
   Description: Visits set weekly to monthly at first, then adjusted.
   Purpose: Keeps “reactivation” from smoldering.
   Mechanism: Timely evaluation prevents fluid and bleeding from lingering.

5. Smoking cessation
   Description: Stop tobacco in all forms; get help if needed.
   Purpose: Smoking accelerates AMD and impairs healing.
   Mechanism: Lowers oxidative stress and vascular injury within the macula.

6. Blood pressure control
   Description: Work with your primary doctor to keep BP in target range.
   Purpose: Prevents pressure spikes that can stress fragile macular vessels.
   Mechanism: Smoother perfusion reduces risk of leakage/bleeding around PEDs.

7. Diabetes and lipid management
   Description: Keep A1c, cholesterol, and triglycerides at goals.
   Purpose: Healthier vessels bleed less and leak less.
   Mechanism: Better endothelial function supports retinal stability.

8. Cardio-metabolic fitness (gentle, regular activity)
   Description: Brisk walking or similar most days, as cleared by your physician.
   Purpose: Supports vascular health and reduces inflammation.
   Mechanism: Improves endothelial nitric oxide and reduces systemic risk drivers.

9. Avoid Valsalva-type strain during active disease
   Description: Be cautious with heavy lifting, forceful coughing/constipation maneuvers.
   Purpose: Limits sudden venous pressure spikes that could aggravate bleeding.
   Mechanism: Gentle intra-thoracic pressure reduces stress on fragile CNV.

10. Medication review with your physicians
    Description: Discuss blood thinners/antiplatelets with your medical team if you’ve had macular bleeding (never stop on your own).
    Purpose: Ensures the right balance between stroke/heart protection and ocular bleeding risk.
    Mechanism: Team-based individualized risk management.

11. UV-blocking eyewear outdoors
    Description: Wraparound sunglasses with UV-A/UV-B protection.
    Purpose: Protects the macula from cumulative light stress.
    Mechanism: Reduces oxidative load on RPE/photoreceptors.

12. Task lighting and contrast optimization at home
    Description: Brighter, glare-free light; high-contrast tools; bold-print labels.
    Purpose: Makes reading and navigation easier despite damaged areas.
    Mechanism: Raises signal-to-noise ratio for remaining retina.

13. Low-vision rehabilitation
    Description: Training with magnifiers, electronic readers, contrast tools, typoscopes, and eccentric viewing techniques.
    Purpose: Maximizes independence when the central area is affected.
    Mechanism: Teaches the brain/eye to use healthier retinal regions.

14. Driving and fall-risk counseling
    Description: Honest discussion of legal driving standards and home safety tweaks.
    Purpose: Prevents injury.
    Mechanism: Matches daily activities to actual visual function.

15. Anti-inflammatory diet pattern (Mediterranean-style)
    Description: Leafy greens, colorful vegetables, legumes, whole grains, fish, nuts, olive oil.
    Purpose: Supports retinal antioxidant defenses and vascular health.
    Mechanism: Delivers lutein/zeaxanthin, omega-3s, polyphenols that support macular metabolism. American Academy of Ophthalmology

16. AREDS2 supplement (when appropriate for AMD stage)
    Description: An evidence-based vitamin/mineral mix for intermediate AMD (not a cure and not for everyone).
    Purpose: Helps slow progression from intermediate to late AMD; does not prevent AMD in healthy eyes.
    Mechanism: Antioxidants and zinc support stressed RPE. Typical components: Vitamin C 500 mg, Vitamin E 400 IU, Lutein 10 mg, Zeaxanthin 2 mg, Zinc (often 80 mg as oxide) plus Copper 2 mg (to offset zinc-related copper deficiency). Ask your doctor which exact formula is right for you, especially if you have a smoking history (avoid beta-carotene). American Academy of Ophthalmology+1

17. Sleep and possible sleep-apnea evaluation
    Description: If snoring/daytime sleepiness exist, seek assessment.
    Purpose: Untreated OSA can worsen vascular stress.
    Mechanism: Better nocturnal oxygenation supports overall vascular health.

18. Weight and insulin-resistance control
    Description: Gradual, sustainable changes in diet and activity.
    Purpose: Lowers systemic inflammation and vascular risk.
    Mechanism: Improves lipid profile and endothelial function.

19. Stress-reduction and blood-pressure smoothing
    Description: Mindfulness, breathing exercises, or counseling as needed.
    Purpose: Reduces BP spikes that can worsen fragile macular vessels.
    Mechanism: Autonomic balance → steadier hemodynamics.

20. Vaccination and general preventive care
    Description: Stay up to date with routine vaccines and medical checkups.
    Purpose: Avoid illnesses that can destabilize cardiovascular status or vision care continuity.
    Mechanism: Fewer systemic flares → steadier eye disease course.

---

Drug treatments

Important: These medicines treat the underlying neovascular AMD and fluid around the tear. They do not “stitch” the torn RPE back together, but they often protect remaining vision by drying the macula and preventing further bleeding or leakage. Your retina specialist selects and adjusts dosing (fixed, PRN, or treat-and-extend) for your eye.

1. Ranibizumab 0.5 mg intravitreal (anti-VEGF monoclonal fragment)
   Usual dosing: 0.5 mg/0.05 mL every 4 weeks at first, then extend to 6–12 weeks as stable.
   Purpose: Suppress abnormal vessel leakage and growth around the tear.
   Mechanism: VEGF-A blockade.
   Key risks: Endophthalmitis (very rare), transient IOP rise, inflammation; systemic VEGF effects are minimal but monitored. Continuing anti-VEGF after a tear may still improve outcomes in many eyes. PubMed CentralPubMed

2. Aflibercept 2 mg intravitreal (VEGF-trap fusion protein)
   Usual dosing: 2 mg/0.05 mL q4 weeks ×3, then q8 weeks (or treat-and-extend).
   Purpose/Mechanism: Binds VEGF-A, VEGF-B, PlGF to reduce leakage.
   Risks: Similar to #1. PubMed

3. Aflibercept 8 mg (Eylea HD) intravitreal
   Usual dosing: 8 mg/0.07 mL q4 weeks ×3 then extend (often to q8–16 weeks in appropriate cases).
   Purpose/Mechanism: Higher molar dose may enable longer intervals while maintaining VEGF suppression.
   Risks: As above (clinic-specific use).

4. Bevacizumab 1.25 mg intravitreal (off-label for AMD)
   Usual dosing: 1.25 mg/0.05 mL monthly at first, then extend if stable.
   Purpose/Mechanism: VEGF-A blockade; widely used and cost-effective.
   Risks: Similar intravitreal injection risks. PubMed Central

5. Faricimab 6 mg intravitreal (dual Ang-2/VEGF-A antibody)
   Usual dosing: 6 mg q4 weeks ×4, then extend (up to q16 weeks in some patients).
   Purpose/Mechanism: VEGF-A suppression plus Ang-2 inhibition may stabilize leaky vessels and the vascular barrier.
   Risks: Similar injection risks; inflammation is uncommon.

6. Brolucizumab 6 mg intravitreal (single-chain anti-VEGF)
   Usual dosing: 6 mg q4 weeks ×3 then q8–12 weeks as tolerated.
   Purpose/Mechanism: High molar VEGF-A suppression with potential long intervals.
   Risks/cautions: Small but real risk of retinal vasculitis/occlusive events; used selectively with careful informed consent.

7. Conbercept 0.5 mg intravitreal (anti-VEGF; widely used in parts of Asia)
   Usual dosing: q4 weeks at first, then extend per response.
   Purpose/Mechanism: VEGF-A/B/PlGF binding similar to aflibercept.
   Risks: As for other anti-VEGF agents.

8. Verteporfin photodynamic therapy (PDT)
   Usual dosing/protocol: IV verteporfin 6 mg/m² followed by 689 nm laser (standard fluence) to the target; used only in selected neovascular patterns (e.g., some PCV/variants) and far less often now.
   Purpose/Mechanism: Photosensitizer + light selectively close abnormal vessels.
   Risks: Back pain during infusion, photosensitivity precautions for 48 h; rare vision drops; can also precipitate RPE tears in high-risk PEDs, so selection is critical. EyeWiki

9. Tissue plasminogen activator (tPA) for associated submacular hemorrhage
   Usual dosing: When dense submacular blood coexists, some surgeons use intravitreal tPA ~18–50 µg with gas, or subretinal tPA ~10–25 µg during vitrectomy, to liquefy and displace blood away from the fovea (not a treatment for the tear itself).
   Purpose/Mechanism: Enzymatically breaks down clot so blood can be moved; usually combined with gas and positioning.
   Risks: Retinal toxicity at higher doses; dosing kept conservative; decisions are highly individualized. PubMedPubMed CentralJAMA Network

10. Topical or oral agents are not standard for RPE tears
    Context: Aside from managing systemic risk factors (e.g., BP, diabetes, lipids), there is no proven pill or eye drop that repairs an RPE tear. Anti-VEGF injections remain the backbone of care; your doctor chooses the molecule/interval best suited to your eye. PubMed Central

Common intravitreal side effects and warnings (for all injectables): brief irritation, small “floater” (vitreous air), transient pressure rise; rare but urgent risks include infection (endophthalmitis), severe inflammation, retinal detachment, or arterial events. Seek urgent care if you develop worsening pain, pus-like discharge, rapidly falling vision, or a curtain/shadow.

---

Dietary “molecular” supplements

Important: Supplements do not heal a tear. Some, when used appropriately in AMD, may slow disease progression. Always coordinate with your ophthalmologist and primary doctor.

1. AREDS2 formulation (for eligible intermediate AMD)
   Dose: Vitamin C 500 mg, Vitamin E 400 IU, Lutein 10 mg, Zeaxanthin 2 mg, Zinc (often 80 mg as zinc oxide) + Copper 2 mg daily.
   Function: Slows progression from intermediate to late AMD.
   Mechanism: Antioxidant and zinc support for stressed RPE; copper offsets zinc-induced deficiency. American Academy of Ophthalmology

2. Lutein (stand-alone when diet is low)
   Dose: Often 10 mg/day (if not already in AREDS2).
   Function: Macular pigment support.
   Mechanism: Blue-light filtering, antioxidant in photoreceptors/RPE. American Academy of Ophthalmology

3. Zeaxanthin (stand-alone when diet is low)
   Dose: Often 2 mg/day (if not already in AREDS2).
   Function/Mechanism: Works with lutein to build macular pigment and reduce oxidative stress. American Academy of Ophthalmology

4. Zinc (with copper)
   Dose: In AREDS2, zinc oxide 80 mg + copper 2 mg; some clinicians use lower-zinc versions.
   Function: Cofactor for antioxidant enzymes, supports RPE metabolism.
   Mechanism: May stabilize complement/oxidative pathways. Coordinate dosing to avoid copper deficiency. American Academy of Ophthalmology

5. Vitamin C
   Dose: 500 mg/day (as in AREDS2).
   Function: Antioxidant recycling of vitamin E; collagen support.
   Mechanism: Scavenges reactive oxygen species in macular tissues. American Academy of Ophthalmology

6. Vitamin E
   Dose: 400 IU/day (AREDS2).
   Function: Lipid-phase antioxidant; protects photoreceptor membranes.
   Mechanism: Breaks lipid peroxidation chain reactions. American Academy of Ophthalmology

7. Omega-3 fatty acids (DHA/EPA from fish oil)
   Dose: Commonly ~1 g/day combined EPA/DHA if diet is low in fish.
   Function: General retinal and vascular support; may help cardiovascular comorbidity.
   Mechanism: Anti-inflammatory lipid mediators; membrane fluidity. (Note: large trials didn’t prove added AMD benefit beyond AREDS2; still reasonable for overall health after physician review.) American Academy of Ophthalmology

8. Saffron extract (Crocus sativus)
   Dose: 20–30 mg/day in small AMD trials.
   Function: May modestly improve contrast sensitivity in some studies.
   Mechanism: Antioxidant/anti-inflammatory carotenoids (safranal/crocins). (Evidence is limited; discuss with your doctor.)

9. Coenzyme Q10 (with standard precautions)
   Dose: 100–200 mg/day used for mitochondrial support in general health contexts.
   Function/Mechanism: Electron transport/antioxidant roles; theoretical RPE support. (Evidence for AMD is limited; coordinate with your physician.)

10. Resveratrol or mixed polyphenols (diet-first approach)
    Dose: Aim for food sources (berries/grapes/cocoa/tea) rather than pills.
    Function/Mechanism: Antioxidant and endothelial effects; supplement evidence is mixed. (Food-based intake preferred.)

---

Regenerative / stem-cell” drugs or approaches

Transparency first: There are no approved immune-booster pills or stem-cell drugs that repair an RPE tear. “Regenerative” approaches are investigational and delivered surgically in clinical trials, not as routine prescriptions.

1. iPSC-derived RPE transplant (investigational)
   What it is: Your own cells are reprogrammed into induced pluripotent stem cells, then turned into RPE and transplanted under the retina.
   Dose/route: Surgical placement of an RPE sheet or suspension; no standard dosing.
   Function/mechanism: Replace missing RPE to support overlying photoreceptors. Early trials are assessing safety/feasibility in advanced AMD. National Eye Institute+1ClinicalTrials.gov

2. hESC-derived RPE patch (investigational)
   What it is: Human embryonic stem cells differentiated into RPE on a scaffold and implanted subretinally.
   Dose/route: One-time surgical implantation; no standardized dose.
   Function/mechanism: Provide a living monolayer to take over RPE duties. Early clinical reports show feasibility; still experimental. National Eye Institute

3. Autologous RPE-choroid patch graft (rare, highly specialized surgery)
   What it is: A small piece of the patient’s own RPE-choroid moved under the macula.
   Dose/route: One-time complex vitreoretinal surgery.
   Function/mechanism: Biological replacement of damaged RPE; used only in select end-stage cases given surgical risks. (Specialist judgment; literature is limited and mixed.)

4. Gene- or complement-pathway modulators (context: GA in AMD)
   What it is: Approved drugs for geographic atrophy slow atrophy spread but do not treat RPE tears; included here to clarify scope.
   Dose/route: Intravitreal; indications are GA, not neovascular AMD with tears.
   Function/mechanism: Modulate complement over-activation; not a repair for RPE tears (avoid off-label expectations).

5. Photobiomodulation (experimental in AMD)
   What it is: Low-level light therapy protocols being studied in AMD.
   Dose/route: Device-based sessions; not standard of care.
   Function/mechanism: Proposed mitochondrial/anti-inflammatory effects; evidence is evolving. Not a treatment for a torn RPE.

6. Systemic “immune boosters” (myth-busting)
   What it is: Over-the-counter tonics claiming to boost immunity.
   Dose/route: Not recommended.
   Function/mechanism: No credible evidence they heal RPE or improve outcomes; can interact with medicines. Focus on vaccines, sleep, nutrition, exercise instead.

---

Procedures/surgeries

1. Intravitreal anti-VEGF injection (office procedure)
   Procedure: The eye is numbed and cleaned; a tiny amount of drug is injected into the vitreous.
   Why done: Backbone therapy to control neovascular AMD activity around a tear and dry the macula.

2. Photodynamic therapy (PDT) with verteporfin (select cases)
   Procedure: Verteporfin is infused, then a specific wavelength laser activates it over the lesion.
   Why done: To selectively close abnormal vessels in carefully chosen patterns (e.g., some PCV variants). Use is far less common today and can itself precipitate tears in high-risk PEDs. EyeWiki

3. Pars plana vitrectomy (PPV) with subretinal tPA for dense submacular hemorrhage
   Procedure: In the OR, the vitreous gel is removed; small volumes of tPA (≈10–25 µg) are delicately injected under the retina and blood is displaced (often with air/gas).
   Why done: To move thick blood away from the fovea so photoreceptors are not poisoned by iron for weeks. It is adjunctive when a big hemorrhage coexists; it does not fix the RPE tear. PubMed Central

4. Pneumatic displacement ± intravitreal tPA
   Procedure: In office or OR, a gas bubble—with or without intravitreal tPA ~18–50 µg—is placed, and you posture so the bubble pushes blood away from the fovea.
   Why done: A less invasive option to clear blood in select cases. PubMedJAMA Network

5. Experimental RPE cell replacement procedures
   Procedure: Subretinal implantation of iPSC-RPE or hESC-RPE as part of a trial.
   Why done: To test whether replacing missing RPE can support vision in advanced disease; still research-only. National Eye Institute+1

---

Practical prevention points

You cannot fully “prevent” an RPE tear, but you can lower risk and protect the rest of your vision.

1. Do not smoke; if you do, get help to quit.

2. Keep blood pressure, lipids, and blood sugar in goal ranges.

3. Keep AMD follow-ups and OCT monitoring as scheduled.

4. Use anti-VEGF injections as advised; do not skip when the eye is active. PubMed Central

5. Use UV-blocking sunglasses outdoors.

6. Eat a Mediterranean-style diet rich in leafy greens and fish. American Academy of Ophthalmology

7. Consider AREDS2 if your AMD stage qualifies (ask your eye doctor). American Academy of Ophthalmology

8. Check your vision quickly at home (Amsler); call promptly if changes appear.

9. Avoid extreme Valsalva strain during active leakage/bleeding phases.

10. Coordinate all medications with your doctors; never stop blood thinners on your own.

---

When to see a doctor urgently

• New or rapidly worsening central blur, distortion, a gray patch, or a “missing” spot in your central vision.

• Sudden drop in vision, especially with a history of a PED or wet AMD.

• After an eye injection: increasing pain, pus-like discharge, increasing redness, big new floaters, or a curtain/shadow—get same-day care (these can signal infection or retinal detachment).

---

Things to eat—and to avoid

Eat more of:

1. Leafy greens (spinach, kale) for lutein/zeaxanthin.

2. Orange/yellow veggies (corn, peppers) for additional carotenoids.

3. Oily fish (salmon, sardines) 2–3×/week for omega-3s.

4. Berries and citrus for vitamin C and polyphenols.

5. Nuts (walnuts/almonds) for healthy fats and vitamin E.

6. Legumes (lentils/beans) for fiber and micronutrients.

7. Whole grains instead of refined carbs.

8. Olive oil as your main fat.

9. Tea/cocoa (unsweetened) for polyphenols.

10. Hydration—water as your default.

Limit/avoid:

1. Smoking (not a food, but #1 vision risk you control).

2. Excess alcohol.

3. Highly processed snacks rich in trans or saturated fats.

4. Sugary drinks and candies (high glycemic load).

5. Excess salt if you have BP issues.

6. Supplements with beta-carotene if you’re a current/former heavy smoker (use AREDS2 without beta-carotene). American Academy of Ophthalmology

7. Mega-dosing random supplements—stick to evidence-based choices and your doctor’s advice. American Academy of Ophthalmology

8. Very high vitamin A intake from pills (toxicity risk).

9. Repeated deep-fried foods.

10. High-sodium instant meals that push BP up.

---

Frequently asked questions

1. Can an RPE tear heal?
   The RPE flap does not knit back together like skin. Surrounding retina can stabilize, and vision may partially recover if the center is spared and the macula is kept dry with treatment. PubMed

2. Did my injection cause the tear?
   Tears can happen spontaneously from the disease and sometimes after anti-VEGF in eyes with large/steep vascularized PEDs. Anti-VEGF remains the main therapy to control the disease and is often continued even after a tear to protect remaining vision. PubMedPubMed Central

3. If I already tore, why keep injecting?
   Because the abnormal vessels can still leak or bleed and damage the rest of the macula. Continuing treatment often improves anatomical and visual outcomes compared with stopping. PubMed Central

4. What is my prognosis?
   It depends on tear size/grade and whether the fovea is involved. Smaller, non-foveal tears do better; large grade-4 tears have a poorer outlook even with treatment. PubMed

5. Is there a pill for this?
   No pill repairs an RPE tear. Pills don’t replace injections for active wet AMD. AREDS2 vitamins can be helpful for intermediate AMD to slow progression—not to fix a tear. American Academy of Ophthalmology

6. Can surgery fix the tear?
   There is no routine surgery to sew the RPE. Some procedures treat associated submacular bleeding (tPA + gas or vitrectomy). Experimental RPE cell transplants are being studied in trials. PubMed CentralNational Eye Institute

7. Do I need both eyes treated?
   Treatment is eye-specific. The fellow eye is watched closely because AMD risk often affects both eyes.

8. How often will I need injections?
   Initially monthly, then extended if the eye stays dry. The schedule is personalized to your OCT findings and symptoms.

9. Is brolucizumab safe?
   It’s effective but carries a small risk of retinal vasculitis/occlusive events; your doctor will discuss pros/cons and alternatives.

10. Are supplements safe with my medicines?
    High-dose supplements can interact with drugs. Review every supplement with your physicians, and use AREDS2-type products only when appropriate. American Academy of Ophthalmology

11. Can stress or blood pressure spikes make it worse?
    Big spikes can stress fragile vessels. Good BP control and stress management are sensible.

12. Can I exercise?
    Yes—most people can do moderate activity approved by their physician. Avoid heavy straining during active bleeding phases.

13. Will blue-light glasses help?
    Strongest protections come from dietary carotenoids (lutein/zeaxanthin) and UV-blocking outdoors; blue-light glasses have uncertain added benefit. American Academy of Ophthalmology

14. Could I be a candidate for a stem-cell transplant?
    Only within a clinical trial at specialized centers. These approaches are experimental; your retina specialist can advise about eligibility. National Eye Institute

15. What is the single most important thing I can do today?
    Keep your scheduled retina visit, follow your injection plan, and stop smoking if you smoke.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 24, 2025.